Joanne Weidhaas

Associate Professor
Therapeutic Radiology
Yale University
E-mail: Joanne.weidhaas@yale.edu

Recent publications:

Kundu ST, Nallur S, Paranjape T, Boeke M, Weidhaas JB*, Slack FJ*.
KRAS alleles: The LCS6 3’UTR variant and KRAS coding sequence mutations in the NCI-60 panel. 
Cell Cycle, 11(2). [Epub ahead of print] (2012)

Grechukhina O, Petracco R, Popkhadze S, Massasa E, Paranjape T, Chan E, Flores I, Weidhaas JB, Taylor HS
A polymorphism in a let-7 microRNA binding site of KRAS in women with endometriosis 
EMBO Molecular Medicine, 3: 206-217 (2012)

Trupti Paranjape, Helen M Heneghan, Aaron Hoffman, Cory Pelletier, Kimberly Geyda, Sunitha Nallur, MJ Kerin, Lyndsay Harris, Daniel Zelterman, Nicola Miller, Yong Zhu, Frank Slack, and Joanne Weidhaas*.
A 3’UTR KRAS microRNA binding site variant as a genetic marker of risk for triple negative breast cancer. 
Lancet Oncology, 12:377-86 (2011)

Chan C, Patel R, Nallur, S, Ratner E, Bacchiocchi, A, Hoyt K, Szpakowski, S, Godshalk, S, Ariyan S, Sznol M, Halaban R, Krauthammer M, Tuck D, Slack FJ, Weidhaas JB*.
MicroRNA signatures differentiate melanoma subtypes. 
Cell Cycle, 10 [epub ahead of print] (2011)

Elkin EB, Klem ML, Gonzales AM, Ishill NM, Hodgson D, Ng AK, Marks LB, Weidhaas J, Freedman GM, Miller RC, Constine LS, Myrehaug S, Yahalom J.
Characteristics and Outcomes of Breast Cancer in Women With and Without a History of Radiation for Hodgkin’s Lymphoma: A mutli-institutional, Matched Cohort Study. 
J Clin Oncol., 29:2466-73 (2011)

Smits KM, Paranjape T, Nallur S, Wouters KA, Weijenberg MP, Schouten LJ, van den Brandt PA, Bosman F, Weidhaas JB*, van Engeland M*.
A let-7 microRNA SNP in the KRAS 3’UTR is prognostic in early-stage colorectal cancer. 
Clin Cancer Res., [Epub ahead of print] (2011)

Ratner E, Keane F, Lindner R, Tassi R, Paranjape T, Glasgow M, Nallur S, Deng Y, Lu L, Stelle L, Sand S, Muller R-U, Bignotti E, Bellone S, Boeke M, Yao X, Pecorelli S, Ravaggi A, Katsaros D, Zelterman D, Cristea M, Yu H, Rutherford T, Weitzel J, Neuhausen S, Schwartz P, Slack F, Santin A, Weidhaas JB*.
A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer. 
Oncogene, [epub ahead of print] (2011)

Elena Ratner, Lingeng Lu, Marta Boeke, Rachel Blitzblau, Rachel Barnett, Cory Pelletier, Sunitha Nallur, Lena J. Chin, Renata Tassi, Pei Hui, Andrew K. Godwin, Herbert Yu, Harvey Risch, Thomas Rutherford, Peter Schwartz, Alessandro Santin, Ellen Matloff, Daniel Zelterman, Frank J. Slack* and Joanne B. Weidhaas*.
A KRAS-variant as a Biomarker of Ovarian Cancer Risk. 
Cancer Research, 15:70: 6509-6515 (2010)

Lena J. Chin, Elena Ratner, Shuguang Leng, Rihong Zhai, Sunitha Nallur, Imran Babar, Roman-Ulrich Muller, Eva Straka, Li Su, Elizabeth A. Burki, Richard E. Crowell, Rajeshvari Patel, Trupti Kulkarni, Robert Homer, Daniel Zelterman, Kenneth K. Kidd, Yong Zhu, David C. Christiani, Steven A.Belinsky, Frank J. Slack* and Weidhaas JB*.
A SNP in a let-7 microRNA complementary site in the KRAS 3UTR Increases Non-Small Cell Lung Cancer Risk. 
Cancer Research, 68: 8535-40 (2008)

Weidhaas JB*, Imran Babar, Phong Trang, Sunitha M. Nallur, Sarah Roush, Michelle Boehm, Erin Gillespie and Frank J. Slack*.
A role for MicroRNAs in Altering Cellular Radiation Resistance.
Cancer Research, 67:11111-6 (2007)